MedTrace Logo

Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

NCT00007956 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-30

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have recurrent or refractory lymphoma.

Conditions

Interventions

BIOLOGICAL

monoclonal antibody mono-dgA-RFB4

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Edward A. Sausville, MD, PhD · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00007956 on ClinicalTrials.gov